EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Phytopharmaceuticals Regulatory requirements and licensing process

Pooja Prajapati, Asmatbanu Pathan, Denish Prajapati

International Journal of Drug Regulatory Affairs · 17.09.2023 · 11 (3) · 43-52

DOI: 10.22270/ijdra.v11i3.615 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Regulatory Affairs, online erschienen am 17.09.2023. Verfasst von Pooja Prajapati und 2 weiteren Autor:innen. Die Arbeit wurde bisher 7-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Since the ancient period, people have used herbal treatments for a wide variety of medical issues. In developing countries, most people utilize herbal remedies to cure a variety of diseases. India, the nation that produces the most medicinal plants, is referred to as the botanical garden of the world. Indian drug regulators are focused on quality in order to uphold the standards for herbal remedies, but manufacturers are struggling to satisfy the higher standards. There are difficulties with standardization, finished formulations, and industry-wide evidence-based practices for AYUSH medicines in India. Phytopharmaceuticals, a modern subclass of medications, contain an enriched fraction with at least four distinct chemical markers with one biomarker. The Central Drugs Standards Control Organization (CDSCO) oversees Phytopharmaceuticals. The Ministry of Health and Family Welfare has released a Gazette Notification GSR 918(E)-Schedule Y, Appendix I(B) regarding Phytopharmaceuticals. This new rule is anticipated to encourage new medication discoveries and evolution using botanicals in a scientific manner and would aid in the modern medical profession's acceptance of Phytopharmaceuticals as a significant alternative to allopathic modern medicine. Phytopharmaceuticals are a well-balanced approach that believes in everything but places emphasis on the revalidation of the plant material's specification, in contrast to conventional pharmaceuticals that suspect everything and AYUSH medicines that trust everything. The purpose of this article is to give specific detail and compiled knowledge about Phytopharmaceutical medicines, regulatory requirements, and regulatory processes.

Zitieren

APA

Prajapati, P., Pathan, A., & Prajapati, D. (2023). Phytopharmaceuticals Regulatory requirements and licensing process. International Journal of Drug Regulatory Affairs, 11(3), 43-52. https://doi.org/10.22270/ijdra.v11i3.615

Vancouver

Prajapati P, Pathan A, Prajapati D. Phytopharmaceuticals Regulatory requirements and licensing process. International Journal of Drug Regulatory Affairs. 2023;11(3):43-52. doi:10.22270/ijdra.v11i3.615

BibTeX
@article{Prajapati2023,
  author = {Prajapati, Pooja and Pathan, Asmatbanu and Prajapati, Denish},
  title = {Phytopharmaceuticals Regulatory requirements and licensing process},
  journal = {International Journal of Drug Regulatory Affairs},
  year = {2023},
  volume = {11},
  number = {3},
  pages = {43--52},
  doi = {10.22270/ijdra.v11i3.615}
}
Kostenlos starten →